RESUMEN
Objective To research and design-an personal dosimeter system to provide data for nuclear radiation injury protection.Methods The overall architecture,hardware module and software of the system were designed with ZigBee wireless network technology and the principle.The system was composed of a terminal node,a router and a coordinator.Results The system could collect the information on nuclear radiation dosage of the serviceman within 1 km,and then the data were uploaded with the wireless network.Conclusion The system gains advantages in low power consumption,low cost,low interference and etc,and plays a very important role for commander to hold the combatants' nuclear radiation dose in the battlefield.In addition the system can also be applied in civilian field to enhance the personal dose management.
RESUMEN
Background and purpose: Docetaxel plus prednisone chemotherapy can improve the patients' survival for castrate-resistant prostate cancer. Angiogenesis inhibitors can also inhibit the growth of tumor. The curative effect of combined treatment is still not clear. This study aimed to evaluate the efficacy of docetaxel plus prednisone combined with thalidomide in treating castrate-resistant prostate cancer (CRPC) patients with bone metastasis. Methods:A total number of 78 CRPC patients were selected in Fuzhou General Hospital from Dec. 2008 to Jun. 2015. Seventy-eight patients were divided into two groups: 40 patients in chemotherapy group (docetaxel plus prednisone) and 38 patients in combined treatment group (docetaxel plus prednisone combined with thalidomide). A total number of 78 subjects were evaluated by the effective rate, the remission rate of bone pain, the prostate specific antigen (PSA) progression-free surviv-al, the overall survival and adverse effect. Results: The response rate (65.79%) and the remission rate of bone pain (86.84%) in combined treatment group were both higher than those in chemotherapy group (40.00% and 60.00%, P0.05). The rates of adverse effects including peripheral neuritis and lethargy in combined treatment group (26.32% and 55.26%) were higher than those in chemotherapy group (5.00% and 17.50%, P<0.05). Conclusion: Thalidomide combined with docetaxel plus prednisone in CRPC patients with bone metastasis can prolong the PSA progression-free survival and overall survival. The adverse effects are mild. It may become a new choice of treatment for CRPC.
RESUMEN
Objective To evaluate long-term changes in health-related quality of life (QOL) of patients with local advanced prostate cancer after intensity modulated radiotherapy (IMRT) combined with androgen deprivation therapy.Methods The patients who met the criteria for this study were enrolled and were treated with IMRT combined with androgen deprivation.The total dose of radiation was 68.2Gy(2.2Gy per fraction).QOL was evaluated before and 3,12,36,48 and 60 months after treatment using the Expanded Prostate Cancer Index Composite(EPIC),a validated tool that assesses four primary domains (urinary,bowel,sexual and hormonal).Results From 2002 to 2007,87 patients were enrolled.At each follow-up time point,the number of cases was 87,87,86,81,75,65,56 and 47,respectively.The median follow-up time was 76.8 months.Compared with baseline assessment,all of four domain scores were declined in follow-up assessments.The mean score of urinary,bowel and hormonal domains were significantly reduced.At 3 months after treatment,the scores of bowel domain were lowest,in which the total,function and symptom scores were 75.7,78.4 and 72.8,respectively.However,there was no statistically significant difference in the mean sexual domain score.The mean change scores in urinary incontinence and obstructive were-13.0±8.3 and-6.12±3.9,respectively.Conclusions IMRT combined with androgen deprivation therapy was well tolerated in patients with local advanced prostate cancer.QOL was decreased in urinary,bowel and hormonal toxicity,most of which could be tolerated in five years.
RESUMEN
Objective To explore the association between the genetic polymorphism of hypoxia inducible factor 1 α (HIF-1α) G1790A and the radiosensitivity of nasopharyngeal carcinoma.Methods A total of 189 patients with nasopharyngeal carcinoma treated with radical radiotherapy were followed-up for 3 years.The patients were divided into cured group with 135 cases and recurrence group with 54 cases by clinical follow-up results.PCR-RFLP was used to determine the mononucleotide genotypes of HIF-1α G1790A.Results The observed genotype frequencies of HIF-1α gene 1790 (G→A) for GG, GA and AA were 70.04% , 20.74% , 2.22% in cured group and 59.26% , 38.89% , 1.85% in recurrence group, respectively.The allele frequencies for G and A were 87.4% , 13.9% in cured groups and 78.7% ,21.3% in recurrence group, respectively, without significant difference in distribution of allele frequencies between the two groups(x2 =6.919, P =0.077).Conclusions The genetic polymorphisms of HIF-1α G1790A might be related with the radiosensitivity of nasopharyngeal carcinoma.
RESUMEN
Objective To determine the effects of hypoxia inducible factor-1α(HIF-1α) expression on postoperative adjuvant radiotherapy in esophageal carcinoma. Methods 95 cases with esophageal carcinoms who received radical operation were analyzed with followed-up data from 1995 to 1998.Expression of HIF-1α in 45 patients with esophageal carcinoma who received radiotherapy after radical operation were deternlined by immunohistochemical method in contrast with 50 patients with esophageal carcinoma received surgery alone.Kaplan-Meier method and COX proportional hazard model were used to analyze.Results The positive expression of HIF-1α in esophageal carcinoma was observed mainly in the nucleus of tumor cells.The positive expression rate of HIF-1α in esophageal carcinoma was 58.9%.The expression of HIF-1α had no relationship with age,sex,histologic subtype and T stage,but had positive relationship with recurrence and distant metastasis.There was significant difference between patients with positive and negative HIF-1α protein expression in surgery alone and postoperation radiotherapy group. COX model analysis showed that HIF-1α had separate and significant impacts on prognosis in surgery group and surgery plus radiotherapy group. Conclusion Over expression of HIF-1α protein suggests a poor prognosis,and has tendency to resist radiotherapy in esophageal carcinoma.
RESUMEN
Objective To investigate the effect of ionization to the expression of HIF-1α and p53 of nasopharyngeal carcinoma (NPC) in anoxia condition. Method Nasopharyngeal carcinoma cell line CNE-1 was divided into three groups, control group, radiation group, and hypoxia plus radiation group. The cell viability was analyzed by MTT method, Immunofluorescent technique was performed to de-termine the expression location of HIF-1α in CNE-1. And the expression of HIF-1α and P53 protein were measured with flow cytometry. Re-sults The results of MTr detection showed that the survival fraction of the control group was the highest. The minimum survival fraction was found in the radiation group (P<0.05). There was no HIF-1αprotein expression in cytoplasm except the radiation plus hypoxia group. With the flow cytometer technique, the expression of HIF-1αprotein in the radiation plus hypoxia group was higher than that in the radiation group. No statistical significance was found between the radiation group and the control group. When detecting the expression of P53 protein with the same technique, the expression of P53 was highest in the hypoxia plus radiation group and lowest in the control group (P<0.05). Conclusion The expression of HIF-1α inducted by Hypoxia can prevent NPC cell from the damages of radiation. The HIF-1α decreases the radiosensitivlty through inducing p53 expression in NPC CNE-1 cell line.
RESUMEN
Objective To investigate whether the tyrosine phosphatase SHP-2 participate in the cell migration induced by IL-1β.Methods Two different reorganized plasmids transfected into the MCF-7,and achieved two different cell lines:SHP-2-GFP-MCF-7 cell lines.SHP-2C＞S-GFP-MCF-7 cell lines.The cell migration was detected by a fluorescence microscope and the expression of E-eadhefin and MMP-9 wee detected by western blotting analysis and RT-PCR.Results The SHP-2-GFP-MCF-7 cell lines showed a higher cell migration ability,and the expression of E-cadherin in the SHP-2-GFP-MCF-7 cell lines was especially lower,neady undetectable.But in this group the expression of MMP-9 was the highest.Conclusion The tyrosine phosphatase SHP-2 participate in the cell migration induced by IL-1β,and maybe produce a marked effect by reinforcing the expression of MMP-9 and reducing the expression of E-cadherin.
RESUMEN
Objective:To investigate the expression of hypoxia inducible factor-1?(HIF-1?) in HepG2 cells cultured under hypoxia for different time periods, and to assess its relationship with vascularization and cell apoptosis. Methods: HepG2 cells were cultured in a medium containing cobalt chloride (125 ?mol/L) for different time periods ( 0, 1, 2, 4, 6, and 8 hours ).RT-PCR was used to measure the expression of HIF-1? mRNA,VEGF mRNA,and bcl-2 mRNA, and bax mRNA at the above time points; Western blot was used to determine the expression of Caspase-3 protein and the activity of Caspase-3 enzyme. Results: After 1-2 hour culture under hypoxia, the expression of HIF-1? mRNA,VEGF mRNA,and bcl-2 mRNA began to increase gradually, peaked at 4 h, and then decreased, but were still higher than that before culture. There was no obvious change in the expression of bax mRNA and the ratio of bcl-2 to bax mRNA expression had a similar change with that of bcl-2 mRNA expression. The changes of Caspase-3 protein/mRNA and Caspase-3 enzyme activity were contrary to that of HIF-1?. Conclusion: HIF-1? may inhibit the apoptosis of hepatic cancer cells through regulating the expression of VEGF, bcl-2, bax, and Caspase-3, and the inhibition is related to the severity of hypoxia.
RESUMEN
Background and purpose:The curative effect with radiotherapy or chemotherapy alone for the patients with unresectable stage Ⅲ non-small-cell lung cancer was poor. The 5-year survival was only 5-10 percent. Concurrent chemoradiotherapy could achieve better local control and overall survival of those patients and it had been reported that the 5-year survival was improved to 15.8 percent, but the toxicity were much more severe at the same time. We prospectively evaluated the efficacy and toxicity of concurrent chemoradiotherapy with low dose weekly paclitaxel for unresectable stage Ⅲ non-small-cell lung cancer and tried to make the regime more tolerable without the deterioration of treatment response. Methods:Forty-eight patients with unresectable stage Ⅲ non-small-cell lung cancer were randomized into low dose weekly paclitaxel group and control group.Both groups were treated by the standard fractionation schedule. All patients were irradiated 2.0 Gy/per fraction,five fractions a week,the total radiation dose was 60-64 Gy for tumor. Patients in the low dose weekly paclitaxel group received chemotherapy with 45 mg/m 2 of paclitaxel on every Monday; the patients in control group received 50 mg/m2 of cisplatin on days 2-4 and day 23-25, and 135 mg/m 2 of paclitaxel on days 1 and 22 concomitant with the radiotherapy.Results:The CR (complete response) rates of low dose weekly paclitaxel and control group were 21% and 13% respectively(P0.05).Conclusions:The patients treated by low-dose weekly paclitaxel group showed that both survival fraction and the period of local tumor control were higher than in control group. Additionally, low dose weekly paclitaxel concomitant with radiotherapy was well tolerated and were not statistically different from control group in terms of toxicities.